Clinical Trials Directory

Trials / Completed

CompletedNCT02770417

Oral β-Alanine Supplementation in Patients With COPD

Oral β-Alanine Supplementation in Patients With COPD: Structural, Metabolic and Functional Adaptations

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Hasselt University · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Accepted

Summary

Preliminary evidence suggest that patients with chronic obstructive pulmonary disease (COPD) suffer from lower-limb muscle dysfunction. This may, at least in part, be due to a combination of physical inactivity and muscle oxidative stress. Pilot data (not published) clearly show that patients with COPD have significantly lower carnosine, which is a pH (acidity-basicity level) buffer and antioxidant, levels in the m. vastus lateralis compared to healthy subjects. Beta-alanine supplementation has shown to increase muscle carnosine in trained and untrained healthy subjects. This study will assess if muscle carnosine can be augmented by beta-alanine supplementation in 40 COPD patients (20 patients receive beta-alanine, 20 patients receive placebo). 10 healthy elderly controls will also be assessed to compare baseline muscle carnosine levels. The aims of this study are to: 1. Investigate baseline muscle carnosine levels to confirm the pilot data in a larger sample of patients with COPD compared with healthy elderly subjects 2. Investigate if beta-alanine supplementation augments muscle carnosine in COPD patients and whether it has an influence on exercise capacity, lower-limb muscle function and quality of life 3. To investigate baseline and post supplementation structural and metabolic muscle characteristics and markers of oxidative stress and inflammation in COPD patients and it's association with muscle carnosine levels

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTbeta-alaninePatients receive beta-alanine
DIETARY_SUPPLEMENTplaceboPatients receive placebo
OTHERcontrolHealthy controls will be assessed to compare baseline muscle carnosine levels

Timeline

Start date
2016-05-01
Primary completion
2019-02-01
Completion
2019-02-01
First posted
2016-05-12
Last updated
2019-02-22

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT02770417. Inclusion in this directory is not an endorsement.